Replimune Group, Inc. filings document regulatory, financing, governance and operating disclosures for a Nasdaq-listed clinical-stage biotechnology company focused on oncolytic immunotherapies. Recent Form 8-K reports cover FDA communications involving the RP1 Biologics License Application, including complete response letters and related Regulation FD disclosures.
The filing record also documents quarterly financial results, corporate presentation materials for RP1 and RP2 programs, amendments to the company’s loan and security agreement, and annual meeting voting results. These disclosures describe Replimune’s development-stage operating profile, capital structure arrangements, stockholder governance matters and material events tied to its cancer immunotherapy pipeline.
Replimune Group, Inc. reported that Chief Accounting Officer Andrew Schwendenman received new equity awards. He was granted an employee stock option for 55,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and then in 36 monthly installments until expiration on April 1, 2036. He was also awarded 36,667 shares of common stock issuable upon settlement of restricted stock units, vesting 25% on May 15, 2027 and then in three annual installments through May 15, 2030, contingent on continued service. Following these grants, he directly holds 114,951 shares of common stock, plus the newly granted options.
Replimune Group, Inc. disclosed that Chief Executive Officer Sushil Patel received new equity awards as part of his compensation. He was granted an employee stock option for 376,860 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. According to the vesting schedule, 25% of the option vests on April 1, 2027, with the remainder vesting in 36 approximately equal monthly installments. Patel also received 251,240 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest 25% on May 15, 2027, with the balance vesting in three approximately equal annual installments through May 15, 2030, contingent on continued service. Following these awards, he directly owns 784,816 shares of common stock. These are compensation-related grants rather than open-market purchases.
Replimune Group director Kapil Dhingra received a grant of stock options covering 44,500 shares of Common Stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest together on April 1, 2027, and no open-market buy or sell occurred.
Replimune Group, Inc. director Paolo Pucci received a grant of stock options covering 44,500 shares of Common Stock. The options have a per-share exercise price of $7.61 and expire on April 1, 2036. All underlying shares vest in a single tranche on April 1, 2027. This is a compensation-related award rather than an open-market purchase or sale, and after this grant Pucci holds 44,500 stock options directly.
Replimune Group, Inc. director Joseph P. Slattery received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. According to the disclosure, all 44,500 underlying shares vest in full on April 1, 2027. Following this grant, Slattery holds 44,500 stock options directly.
Replimune Group, Inc. director Veleka Peeples-Dyer received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest on April 1, 2027, making this a compensation-related, non-market transaction.
Replimune Group, Inc. Chief Financial Officer Emily Luisa Hill reported receiving new equity awards. She was granted an employee stock option for 75,000 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. Twenty-five percent of this option vests on April 1, 2027, with the rest vesting in 36 approximately equal monthly installments.
Hill was also granted 50,000 restricted stock units (RSUs), each representing one share of common stock. Twenty-five percent of these RSUs vest on May 15, 2027, with the remainder vesting in three approximately equal annual installments until May 15, 2030, subject to continued service. Following the RSU grant, her direct common stock holdings increased to 244,368 shares.
Replimune Group, Inc. director Weinand Dieter received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036.
According to the filing, these options vest in full on April 1, 2027. Following this grant, Dieter holds 44,500 derivative securities directly, reflecting a compensation award rather than an open-market purchase.
Replimune Group, Inc. Chief Commercial Officer Christopher Sarchi sold 6,500 shares of common stock in an open-market transaction. The shares were sold on April 2, 2026 at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating it was scheduled in advance. After this sale, Sarchi beneficially owns 151,588 shares of Replimune common stock, including restricted stock units, and holds options to acquire an additional 250,425 shares, 142,555 of which are currently exercisable.
REPL filed a Form 144 notice relating to proposed sales of Common shares. The filing lists a broker-dealer, J.P. Morgan Securities LLC, and includes a filing date of 04/02/2026. The excerpt shows scheduled RSU vesting entries on 11/15/2023, 11/15/2024, and 11/15/2025 with specified share amounts.